Sevirumab

Sevirumab
Monoclonal antibody
Type	?
Source	Human
Target	CMV
Clinical data
ATC code	none;
Identifiers
CAS Number	138660-96-5 ;
ChemSpider	none;
UNII	HV6MT68KKF;
KEGG	D05831;
ChEMBL	ChEMBL2108881;
	(verify)

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Sevirumab (MSL-109) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS.^[1]^[2]

References

^ Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, et al. (November 2004). "A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis". Antiviral Research. 64 (2): 103–11. doi:10.1016/j.antiviral.2004.06.012. PMID 15498605.
^ Clinical trial number NCT00000836 for "A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)" at ClinicalTrials.gov

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[1] Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, et al. (November 2004). "A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis". Antiviral Research. 64 (2): 103–11. doi:10.1016/j.antiviral.2004.06.012. PMID 15498605.

[2] Clinical trial number NCT00000836 for "A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)" at ClinicalTrials.gov

[1]

[2]